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Calgary, Alberta, Canada, 6 Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, Jouy-en-
Josas, France, 7 Department of Infectious Disease, Imperial College London, London, United Kingdom,
8 MRCCentre for Molecular Bacteriology and Infection, Imperial College London, London, United Kingdom,
9 Department of Infection, Immunity and Cardiovascular disease, Medical School, University of Sheffield,
Sheffield, United Kingdom
☯ These authors contributed equally to this work.
* s.a.renshaw@sheffield.ac.uk (SAR); s.foster@sheffield.ac.uk (SJF)
Abstract
Staphylococcus aureus is a human commensal organism and opportunist pathogen, caus-
ing potentially fatal disease. The presence of non-pathogenic microflora or their compo-
nents, at the point of infection, dramatically increases S. aureus pathogenicity, a process
termed augmentation. Augmentation is associated with macrophage interaction but by a
hitherto unknown mechanism. Here, we demonstrate a breadth of cross-kingdommicroor-
ganisms can augment S. aureus disease and that pathogenesis of Enterococcus faecalis
can also be augmented. Co-administration of augmenting material also forms an efficacious
vaccine model for S. aureus. In vitro, augmenting material protects S. aureus directly from
reactive oxygen species (ROS), which correlates with in vivo studies where augmentation
restores full virulence to the ROS-susceptible, attenuated mutant katA ahpC. At the cellular
level, augmentation increases bacterial survival within macrophages via amelioration of
ROS, leading to proliferation and escape. We have defined the molecular basis for augmen-
tation that represents an important aspect of the initiation of infection.
Author summary
S. aureus is a commensal inhabitant of the human skin and nares. However, it can cause
serious diseases if it is able to breach our protective barriers such as the skin, often via
wounds or surgery. If infection occurs via a wound, this initial inoculum contains both
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the pathogen, other members of the microflora and also wider environmental microbes.
We have previously described “augmentation”, whereby this other non-pathogenic mate-
rial can enhance the ability of S. aureus to lead to a serious disease outcome. Here we have
determined the breadth of augmenting material and elucidated the cellular and molecular
basis for its activity. Augmentation occurs via shielding of S. aureus from the direct bacte-
ricidal effects of reactive oxygen species produced by macrophages. This initial protection
enables the effective establishment of S. aureus infection. Understanding augmentation
not only explains an important facet of the interaction of S. aureus with our innate
immune system, but also provides a platform for the development of novel prophylaxis
approaches.
Introduction
Staphylococcus aureus exists in a polymicrobial environment, primarily as a human commen-
sal organism [1–3], but can also cause disease after a breach in host defences, often via localised
tissue injury [4]. S. aureus causes a spectrum of disease, from minor skin infections to life-
threatening bacteraemia: infections that are increasingly difficult to treat due to antibiotic
resistance [5]. Human innate immune defences, primarily phagocytes, play a crucial role in
preventing serious S. aureus disease. However, during infection S. aureus can reside within,
and escape from, an intraphagocyte niche [6–8]. Similar to other intracellular pathogens
[9,10], this can lead to a population bottleneck, where most bacteria are effectively killed by
phagocytes, but a small proportion survive, enabling continued infection [11]. This results in
the emergence of clonal bacterial populations, which expand from the small numbers surviv-
ing the population bottleneck. In the murine sepsis model, liver-resident macrophages known
as Kupffer cells are the basis of this population bottleneck and subsequent bacterial clonality
[12,13]. Macrophages are crucial for defence against S. aureus, exposing bacteria to an array of
bactericidal mechanisms, including ROS, deleterious enzymes and antimicrobial peptides
[14]. After phagocytosis, NADPH oxidase (NOX2) produces superoxide (O2
-) [15], which is
converted to hydrogen peroxide (H2O2) and hydroxyl radical (�OH). Hypochlorous acid
(HOCl) is generated from H2O2 via the enzyme myeloperoxidase (MPO) [16]. Reactive nitro-
gen species (RNS) are produced by inducible nitric oxide synthase (iNOS), creating nitric
oxide (NO�) which can then react with O2
- to form peroxynitrite (ONOO-) [17]. All reactive
species cause bacterial damage, but HOCl and H2O2may be key in vivo, as both are efficacious
against biofilms [18,19]. S. aureus uses several approaches to resist ROS/RNS: two superoxide
dismutases detoxify O2
- [20], catalase removes H2O2 [21], alkyl hydroperoxidase acts to reduce
H2O2,ONOO
- and organic peroxides [22], and staphylococcal peroxidase inhibitor (SPIN)
inhibits MPO therefore blocking HOCl formation [23]. Many S. aureus-ROS studies focus on
neutrophils, since chronic granulomatosis disease (CGD) highlights ROS as vital in neutrophil
bacterial clearance [24]. Nevertheless, ROS are also important in tissue macrophages [25] for
defence against S. aureus [26].
Augmentation is a recently described phenomenon whereby human skin commensals
enhance S. aureus pathogenesis [12]. S. aureus bloodstream infection in mice can be aug-
mented by either Gram-positive commensals, their purified peptidoglycan (PGN) or a natural
mix of skin flora [12]. In this example of microbial crowdsourcing, only S. aureus benefits, not
the non-pathogenic commensals, which succumb. During murine sepsis, augmenting material
is co-phagocytosed with S. aureus in Kupffer cells, resulting in increased bacterial survival and
the subsequent formation of clonal liver microabscesses [12], with the potential to seed other
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organs in the body [13]. In Kupffer cells, augmentation is associated with reduced oxidation
and, importantly, augmentation is not observed in transgenic mice lacking functional NOX2,
defining a pivotal role for ROS in this phenomenon. However, major signalling receptor-
mediated mechanisms (including NOD1, NOD2, TLRs and the inflammasome) did not
account for augmentation [12]. To elucidate the molecular mechanism(s) underpinning aug-
mentation, we sought to define the breadth of materials able to enhance S. aureus infection
and investigate whether augmentation occurs for other human pathogens. Using in vitro and
in vivo studies, we demonstrate that the molecular basis for augmentation is absorption of
ROS by augmenting material, shielding S. aureus from macrophage-mediated killing.
Results
A broad range of pathogen-derived materials augment S. aureus infection
Previously, we have shown that S. aureus pathogenesis can be augmented by live Gram-posi-
tive skin commensals, purified PGN, or natural skin flora [12]. To determine the breadth of
material able to augment S. aureus pathogenesis, we used the murine sepsis model and co-
injection of a low S. aureus infectious dose with potential augmenting materials. Increased bac-
terial numbers in the liver is a key marker of augmented infection, with accompanying weight
loss and/or increased kidney bacterial load in severe cases [12]. We first tested Gram-negative
bacteria Escherichia coli and Roseomonas mucosa, as part of the human microflora [27,28],
with heat-killed (HK)Micrococcus luteus as a positive control. Addition of HKM. luteus, E.
coli or R.mucosa significantly increased S. aureus counts in the liver in comparison to S.
aureus-only infected mice (Figs 1A–1C, 1E and S1A–S1C). On average S. aureus liver counts
are greatly increased from the inocula (of 1x106 CFU) to 1.25x108 CFU in augmented infec-
tions, in comparison to 1x106 in control infections. Interestingly, E. coli benefits from the pres-
ence of S. aureus, with an increase in E. coli counts in the liver, although these CFU counts are
reduced in comparison to the injected E. coli inoculum (Fig 1B). In order to assess whether
cross-kingdom materials could augment staphylococcal infection, we tested HK Cryptococcus
neoformans and live fungi in the murine sepsis model. Addition of HK C. neoformans signifi-
cantly increased S. aureus liver numbers (Figs 1D, 1E and S1D). In contrast, Saccharomyces
cerevisiae, an occasional human commensal which rarely becomes pathogenic [29,30], did not
increase S. aureus liver or kidney numbers, but did enhance mouse weight loss (Figs 1E and
S1E–S1G). Together these data demonstrate that S. aureus pathogenicity can be enhanced by a
wider range of microorganisms than has previously been shown.
Can infection with other human pathogens be augmented?
Next, we tested whether augmenting material was able to increase the virulence of a range of
human pathogens: Enterococcus faecalis, an opportunist pathogen capable of residing within
macrophages [31]; Streptococcus pneumoniae, which is able to survive within phagocytes and
experiences a population bottleneck which seeds further infection [32]; Pseudomonas aerugi-
nosa, which survives within macrophages [33]; and Streptococcus pyogenes, which can survive
and escape from within host cells [34]. During murine sepsis, liveM. luteus augmented E. fae-
calis infection (of 5x107 CFU) with a significant increase in liver and lung bacteria compared
to E. faecalis alone (Figs 1F, 1G and S1H–S1L). Furthermore,M. luteus PGN augmented a
larger E. faecalis inoculum (1x108 CFU), although it did not at 5x107 CFU (S1M–S1R Fig). In
both cases of E. faecalis augmentation, the liver bacterial number never increased higher than
the inoculum. Pathogenesis of S. pneumoniae and P. aeruginosa was not increased by the pres-
ence ofM. luteus PGN in sepsis models (Figs 1G and S2A–S2F). AlsoM. luteus PGN did not
alter mouse weight or S. pyogenes numbers in an intra-muscular leg infection model (S2G and
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S2H Fig). These data suggest that augmented infections which result in increased pathogen
numbers from the inoculummay be specific to S. aureus and a facet of its particular interaction
mechanism with the host.
Augmentation requires spatial and temporal co-localisation of S. aureus
and augmenting material
Macrophages and ROS are implicated in augmentation [12], suggesting that augmenting mate-
rial influences S. aureus infection within the phagocyte. To test whether augmentation in the
murine sepsis model requires concomitant inoculation of augmentor/pathogen, PGN was
injected at a range of timepoints before and after S. aureus infection.
PGN was injected into mice at 24, 6 or 1 hours before, or 0, 6, 24 or 48 hours after S. aureus
infection (Fig 2A–2F). S. aureus liver bacterial numbers were significantly increased when
PGN was co-injected, but not when PGN was injected at all time-points before (Fig 2A–2C) or
after (Fig 2D–2F) S. aureus, suggesting that co-administration is required. No change in weight
or kidney bacteria was observed for PGN injected before (Figs 2C and S3A, S3B), while, for
PGN injected after S. aureus, no change in kidney bacteria was observed, but significant reduc-
tions in mouse weight loss were observed at 6 and 24 hours (Figs 2F and S3C, S3D). Together
these data demonstrate that to increase S. aureus pathogenesis, augmenting material must be
present concomitantly with S. aureus.
The requirement for concomitant administration of S. aureus and augmenting material
suggested that they are likely co-phagocytosed. To examine this, the amount of augmenting
Fig 1. Breadth of the augmentation phenomenon, from S. aureus to other pathogens. Co-injection of low dose S. aureus (SA 1x106 CFU) with heat-killed
M. luteus (HKML equivalent of 1x108 CFU) into mice: liver CFU (n = 5 per group, median value shown, two-tailed Mann-Whitney test), ��p<0.008 B Co-
injection of low dose S. aureus (SA 1x106 CFU) with E. coli (EC 5x106 CFU) into mice: liver CFU, S. aureus, circles; E. coli triangles (n = 8–10 per group,
median value shown, two individual two-tailed Mann-Whitney tests), ���p<0.0003 C Co-injection of low dose S. aureus (SA 1x106 CFU) with R.mucosa
(RM 2x108 CFU) into mice: liver CFU (n = 5 per group, median value shown, two-tailed Mann-Whitney test), �p<0.05D Co-injection of low dose S. aureus
(SA 1x106 CFU) with heat-killed C. neoformans (CN 750 μg) into mice: liver CFU (n = 9–10 per group, median value shown, two-tailed Mann-Whitney
test), ��p<0.006 E Summary heat-map for microorganisms tested for augmenting ability in S. aureus infection, showing significant changes in liver CFUs
and weight change F Co-injection of low dose E. faecalis (EF 5x107 CFU) withM. luteus (ML 2x108 CFU) into mice: liver CFU (n = 10 per group, median
value shown, two-tailed Mann-Whitney test), ����p<0.0001G Summary heat-map of alternative pathogens tested for ability to be augmented, with addition
of PGN orM. luteus, showing significant changes in liver CFUs and weight change. In all cases liver CFUs were enumerated at 3 days post-infection.
https://doi.org/10.1371/journal.ppat.1009880.g001
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Fig 2. Augmenting material must be present at the same time and location as S. aureus to enhance infection. A-CMice were
intravenously injected with 500 μgM. luteus PGN 24 hours, 6 hours or 1 hour before infection with 1x106 S. aureus, or at the same time as
S. aureus, or with S. aureus aloneADiagram of experimental protocol B liver CFUs, enumerated at 72 hpi (n = 7 per group, median value
shown, Kruskal-Wallis test with Dunn’s post-test), �p<0.05 C Summary heat-map for augmenting ability of PGN added before S. aureus
infection, showing significant changes in liver CFUs and weight changeD-FMice were intravenously injected with 500 μgM. luteus PGN
48 hours, 24 hours or 6 hours after infection with 1x106 S. aureus, or at the same time as S. aureus, or with S. aureus aloneDDiagram of
experimental protocol E liver CFUs, enumerated at 72 hpi (n = 5 per group, median value shown, Kruskal-Wallis test with Dunn’s post-
test) �p<0.05 F Summary heat-map for augmenting ability of PGN added after S. aureus infection, showing significant changes in liver
CFUs and weight changeG-K Zebrafish larvae injected with 400 CFU S. aureus, 5 ng ofM. luteus PGN, or both. The larvae have
fluorescent macrophages (red) and were injected with fluorescent S. aureus (green) and/or fluorescently labelledM. luteus PGN (blue)G-I
Images of infected larvae at 2 hpi showing macrophages containing S. aureus, scale 6.9 μm, greyscale insets depict location of fluorescence
signal within the hatched box of the main image, for ease of visualisation (G),M. luteus peptidoglycan scale 6.9 μm (H), or both scale
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material within individual phagocytes in vivo was examined. A zebrafish transgenic line with
fluorescent macrophages was used: Tg(mpeg:mCherry.CAAX)sh378 [35]. Augmentation has
previously been shown to occur during systemic infection of zebrafish larvae [12]. Larvae were
infected with GFP fluorescent S. aureus and/or fluorescently stained PGN. Macrophages
phagocytosed injected material in each individually injected group (Fig 2G and 2H) and S.
aureus and PGN were co-localised when present within the same macrophage (Figs 2I and
S3E). Macrophages were imaged and the area of phagocytosed fluorescent materials was quan-
tified using Fiji. The area taken up by S. aureus within individual macrophages was not altered
when PGN was present (Fig 2J). However, the area of PGN was significantly increased in the
presence of S. aureus, in comparison to PGN injected alone (Fig 2K). Thus, augmentation does
not alter the level of S. aureus phagocytosis in vivo, however, it appears that macrophages
which engulf S. aureus also phagocytose more augmenting material.
Augmenting material protects S. aureus from ROS in vitro
Since augmentation does not occur in the absence of NOX2, and Kupffer cells have reduced
ROS levels in augmented S. aureus infection [12], we hypothesised that inactivation of ROS by
augmenting material could be the mechanism by which S. aureus survival is enhanced with an
ensuing increase in pathogenesis. We therefore tested whether augmenting material protects S.
aureus from specific ROS and RNS in vitro, using H2O2, sodium hypochlorite (a source of
HOCl), peroxynitrite, and methyl viologen (a source of superoxide) (Fig 3A). S. aureus survival
in liquid culture in vitro was measured following ROS exposure, with or withoutM. luteus
PGN. Exposure to each ROS led to a significant reduction in S. aureus numbers, while addition
of PGN significantly increased S. aureus survival in the presence of H2O2, HOCl and peroxyni-
trite, but not methyl viologen (Figs 3B–3D and S4A).
We have previously shown that live bacteria augment S. aureus infection [12], as such, we
hypothesised thatM. luteus would promote S. aureus survival in the presence of ROS.M. luteus
was used at 100 times the concentration of S. aureus. Addition of liveM. luteus led to signifi-
cantly increased survival of S. aureus after H2O2, HOCl and peroxynitrite treatments, but not
methyl viologen (S4B–S4E Fig). It was possible that liveM. luteus was mediating augmentation
via production of ROS defence enzymes, such as catalase. Addition of HKM. luteus increased
S. aureus survival when exposed to HOCl but not H2O2 and peroxynitrite (Figs 3E and S4B–
S4D). To determine if the lack of effectiveness of HKM. luteus was due to the availability of
ROS active moieties the ratio of augmenting material was raised (ratio of 1:2500), which signif-
icantly increased S. aureus survival following exposure to H2O2 or peroxynitrite (Fig 3F and
3G). Thus, both live and HKM. luteus can protect S. aureus from ROS. It appears that H2O2 or
peroxynitrite are effectively deactivated by enzymes present in liveM. luteus; although these
enzymes promote augmentation they are not required.
Thus, augmenting material may act as a buffer to react with, and therefore detoxify, ROS. If
this is so, pre-treatment of augmenting material with ROS would diminish its effect. To test
this, liveM. luteus were pre-treated with ROS prior to inclusion in the in vitro liquid culture
assay. HOCl pre-treatedM. luteus showed a clear loss of protective ability, with no surviving
bacteria, in comparison to live or HKM. luteus (Fig 3E). For both H2O2 and peroxynitrite, the
level of S. aureus survival with addition of ROS-treatedM. luteus was ~10–20%, whereas with
HKM. luteus this was ~100% (Fig 3F and 3G). This indicates that augmenting material has a
finite capacity to react with ROS and, in so doing, loses its ability to protect S. aureus.
10 μm (I), J Area of macrophage taken up by S. aureus at 2 hpi (n = 3, 14–21 larvae per group, unpaired t-test)K Area of macrophage
taken up byM. luteus PGN at 2hpi (n = 3, 11–21 larvae per group, two-tailed unpaired t-test, ���p<0.0004).
https://doi.org/10.1371/journal.ppat.1009880.g002
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Fig 3. Augmenting material protects S. aureus from ROS in vitro. A Reactive oxygen species generated in the
oxidative burst, ROS highlighted in red are examined B-D Following ROS exposure, percentage survival of S. aureus
alone (5x104 CFU/mL), or withM. luteus PGN (1.25 mg) B hydrogen peroxide (n = 3, error bars show mean +/- SD,
one-way ANOVA test with Tukey’s post hoc test) �p<0.05 C sodium hypochlorite (n = 3, error bars showmean +/-
PLOS PATHOGENS Augmentation of S. aureus infection
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Augmenting material restores virulence to ROS susceptible S. aureus in
vitro and in vivo
S. aureusmutants lacking oxidative stress resistance mechanisms are susceptible to ROS and
attenuated in pathogenesis [20,21]. We used a S. aureus katA ahpC to map which ROS resis-
tance mechanisms are important for S. aureus survival and to test the ability of augmenting
material to rescue this strain. The place of the ROS resistance enzymes investigated here in
detoxifying the oxidative burst is shown in Fig 4A. S. aureus katA ahpC would be expected to
have a reduced ability to detoxify H2O2, organic peroxides and peroxynitrite, and is more sen-
sitive to peroxides in vitro [21]. S. aureus katA ahpC was protected from H2O2 by liveM.
luteus, but not by HK or H2O2-treated cells (Fig 4B), as were individual katA or ahpCmutants
(S5A and S5B Fig). When katA ahpC was exposed to HOCl, katA ahpC survival was signifi-
cantly increased from ~0.2% to ~100% with the addition ofM. luteus and to ~68% with HKM.
luteus, but not ROS-treatedM. luteus which remained at ~4.4% survival (S5C Fig). The role of
ROS resistance was then tested in vivo using the murine sepsis model. The katA, ahpC and
katA ahpC strains were attenuated, with significantly fewer liver bacteria recovered for ahpC
and katA ahpC, and kidney bacteria for katA ahpC and katA, with all strains causing signifi-
cantly reduced weight loss in comparison to wild-type (S5D–S5I Fig).
To test whether ROS-susceptible S. aureus could be augmented in vivo, a low dose (1x106
CFU) of katA ahpC was injected with or without HKM. luteus (1x108 CFU). In the presence
of augmenting material, the katA ahpC strain had an exceptionally large and significant
increase in liver bacterial numbers from 0 CFU to ~3x107 CFU, levels seen in augmented wild-
type S. aureus infections, but no significant change in weight loss or kidney bacterial numbers
(Figs 4C and S5J, S5K). Thus S. aureus katA ahpC can not only be augmented but also this
leads to loss of attenuation in the liver. This further supports the assertion that augmentation
occurs in the liver and is associated with the ability of the bacteria to survive ROS, as well as
that augmentation also occurs during the initiation of infection. ROS resistance is additionally
required for later infection stages, as S. aureus katA ahpC in the presence of augmenting mate-
rial does not recover to parental bacterial numbers in the kidney.
To examine the role of HOCl in augmented S. aureusmurine infection, MPO knock-out
mice (MPO-/-) were infected alongside wild-type controls. Interestingly, we observed a signifi-
cant increase in liver bacterial numbers in MPO-/-mice in comparison to wild-type mice (Fig
4D), demonstrating that MPO-/-mice were more susceptible to S. aureus infection. This sug-
gests that MPO activity is a crucial component of the host defence in this model. Augmented
infections for both wild-type and MPO-/-mice had significantly more liver bacterial numbers
and increased weight loss than respective non-augmented infections (Figs 4D and S5L). There-
fore, loss of MPO did not inhibit the ability of augmenting material to enhance S. aureus infec-
tion, suggesting that HOCl amelioration, at least alone, is not sufficient for augmentation in
vivo.
SD, one-way ANOVA test with Tukey’s post hoc test), ��p<0.01; ���p<0.005D peroxynitrite (n = 3, error bars show
mean +/- SD, one-way ANOVA test with Tukey’s post hoc test), ���p<0.005; ����p<0.0001 E Following sodium
hypochlorite exposure, percentage survival of S. aureus alone (5x104 CFU/mL), with heat-killedM. luteus (equivalent
of 5x106 CFU/mL) or ROS killedM. luteus (equivalent of 5x106 CFU/mL) (n = 3, error bars showmean +/- SD, one-
way ANOVA test with Tukey’s post hoc test), �p<0.05 F-G Following ROS exposure, percentage survival of S. aureus
alone (5x104 CFU/mL), with heat-killedM. luteus (equivalent of 1.25x108 CFU/mL), or ROS killedM. luteus
(equivalent of 1.25x108 CFU/mL) F hydrogen peroxide (n = 3, +/-SD, one-way ANOVA test with Tukey’s post hoc
test), �p<0.05; ����p<0.0001G peroxynitrite (n = 3, +/-SD one-way ANOVA test with Tukey’s post hoc test), �p<0.05;
��p<0.003.
https://doi.org/10.1371/journal.ppat.1009880.g003
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Augmenting material protects S. aureus by inactivating ROS in
macrophages
Augmentation occurs at the initiation of infection by circumventing the deleterious effects of
ROS in vivo. To determine how these manifest at the cellular level, we used a murine macro-
phage cell line. Time-lapse imaging of RAW264.7 cells infected with fluorescent S. aureus were
used to examine whether bacteria surviving within macrophages may represent the source of
the microabcesses that occur as a product of augmentation [12]. In the presence of augmenting
material, intracellular S. aureus survival and growth were observed within individual macro-
phages, which eventually led to host cell death and formation of large extracellular accumula-
tions of bacteria, referred to here as bacterial masses (Fig 5A). Using a high-throughput assay
to examine S. aureusmass formation, RAW264.7 cells were infected with S. aureus with or
without HKM. luteus at a ratio of 1:10, a lower ratio than was used in the preceding in vitro
and in vivo work, to limit cell toxicity. Despite this, the number of masses was significantly
increased in the augmented group in comparison to S. aureus infection alone (Fig 5B). We
next examined the ratio of augmenting material to S. aureus, using an augmenting material
ratio of 10, 5, 2.5, 0.5 and 0.05 to S. aureus, with increased numbers of masses forming in the
presence of higher concentrations of augmenting material (Fig 5C). Higher S. aureus levels
also led to increased mass formation (Fig 5D). These data demonstrate dose-dependent
Fig 4. S. aureus strains susceptible to ROS are augmented in vitro and in vivo. A Reactive oxygen species generated in
the oxidative burst, highlighting where KatA and AhpC action occurs B Following hydrogen peroxide exposure,
percentage survival of S. aureus katAahpCmutants alone (5x104 CFU/mL), or with liveM. luteus (5x106 CFU/mL), heat-
killedM. luteus (equivalent of 5x106 CFU/mL) or ROS killedM. luteus (equivalent of 5x106 CFU/mL), (n = 3, error bars
show mean +/- SD, one-way ANOVA test with Tukey’s post hoc test), ���p<0.0002; ����p<0.0001 C Co-injection of low
dose S. aureus katAahpC (1x106 CFU) with heat-killedM. luteus (equivalent of 1x108 CFU) into mice: liver CFU,
enumerated at 3 days post-infection (n = 5 per group, median value shown, two-tailed Mann-Whitney test), �p<0.05D
Co-injection of low dose S. aureus (SA 2x105 CFU) withM. luteus PGN (ML PGN 500 μg) into wild-type (WT) control
mice or MPO-/-mice: liver CFU, enumerated at 3 days post-infection (n = 9 per group, median value shown, individual
two-tailed Mann-Whitney tests), �p<0.05, ��p<0.002, ���p<0.0006.
https://doi.org/10.1371/journal.ppat.1009880.g004
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Fig 5. Augmenting material protects S. aureus from reactive oxygen species in macrophages. A Images of GFP-S. aureusmass formation within
RAW264.7 cells, scale 20 μm B RAW264.7 cells infected with GFP S. aureus (MOI 5) with or without heat-killedM. luteus (MOI 50), (n = 4), ����p<0.0001 C
RAW264.7 cells infected with GFP S. aureus (MOI 5) with or without heat-killedM. luteus (ratio to S. aureus, 10, 5, 2.5, 0.5 or media control), (n = 4),
��p<0.008; ����p<0.0001D RAW264.7 cells infected with GFP S. aureus (MOI 5, 2.5, 1.25, 0.25, 0.025 or media control) with or without of heat-killedM.
luteus (MOI 50), (n = 4), ��p<0.003; ���p<0.0008; ����p<0.0001 E-FMDMs infected with GFP S. aureus (MOI 5) with or without heat-killedM. luteus (MOI
50) E images of GFP S. aureusmass formation within humanMDMs, scale 20 μm F number of S. aureusmasses observed (n = 3), ��p<0.003G RAW264.7
cells infected with GFP S. aureus (MOI 5) in the presence or absence of heat-killedM. luteus (MOI 50), either with or without DPI (2 μM), (n = 4),
�p<0.05;���p<0.0004; ����p<0.0001H RAW264.7 cells infected with GFP S. aureus (MOI 5) in the presence or absence of heat-killedM. luteus (MOI 50),
either with or without apocynin (500 μM), (n = 4), ����p<0.0001 I RAW264.7 cells infected with GFP S. aureus (MOI 5) in the presence or absence of heat-
killedM. luteus (MOI 50), either with or without mitoTEMPO (1 μM), (n = 4, non-significant) J RAW264.7 cells infected with GFP S. aureus (MOI 5) with or
without heat-killedM. luteus (MOI 50) with Hydrop used to visualise hydrogen peroxide (n = 4, violin plot with median values shown), ��p<0.007;
���p<0.0004K RAW264.7 cells infected with CellROX-stained GFP S. aureus (MOI 50) to visualise intracellular oxidation in the presence or absence of heat-
killedM. luteus (MOI 50), (n = 4, violin plot with median values shown), ����p<0.0001. In panels B, F, H, I and K, a two-tailed MannWhitney test was used,
in panels C, D, G, and J, a Kruskal-Wallis test with Dunn’s post hoc test was used. Where used, error bars show mean +/- SD.
https://doi.org/10.1371/journal.ppat.1009880.g005
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augmentation by HK bacteria of S. aureus survival and proliferation within macrophages.
Finally, we used human monocyte-derived macrophages (MDMs) in the time-lapse S. aureus
mass formation assay. S. aureus was able to survive, proliferate and escape fromMDMs (Fig
5E). Similarly, S. aureusmass formation fromMDMs was significantly increased in the pres-
ence of augmenting material (Figs 5F and S6A). Augmenting material therefore increases the
capacity of S. aureus to overwhelm human macrophages.
To examine the importance of ROS production, the mass formation assay was evaluated fol-
lowing treatment with NOX2 inhibitors DPI or apocynin, using concentrations which did not
inhibit S. aureus growth (S6B and S6C Fig). Addition of DPI or apocynin significantly reduced
the level of augmentation compared to the untreated controls (Fig 5G and 5H), but treatment
with a specific scavenger of mitochondrial superoxide (mitoTEMPO) did not (Fig 5I). This
confirms that ROS production, specifically in phagosomes, is important for augmentation of S.
aureus infection within macrophages. Our in vitro assays showed that augmenting material
protects S. aureus from ROS. Therefore, we used a specific fluorescent probe, Hydrop, to
examine levels of H2O2 within infected RAW264.7 macrophages. The Hydrop assay showed
significantly reduced H2O2 levels in RAW264.7 cells infected with S. aureus and HKM. luteus,
in comparison to S. aureus alone (Figs 5J and S6D). To further examine how augmentation
affects oxidation of the bacteria, RAW264.7 macrophages were infected with GFP S. aureus
stained with CellROX, a dye which becomes fluorescent when oxidised by ROS. There were
significantly more oxidised S. aureus events in macrophages infected with S. aureus alone than
those infected with S. aureus alongside HKM. luteus (Figs 5K and S6E). Together these data
demonstrate ROS levels are reduced in the presence of augmenting material, suggesting this
material acts to inactivate ROS.
Can augmentation be exploited for vaccine development?
S. aureus vaccine development has been unsuccessful, in part due to animal models not being
representative of human disease and high variability in infection outcome [36]. Natural
human infection with S. aureus emerges from a polymicrobial environment. We therefore
tested if the augmented infection model (where augmenting material represents polymicrobial
species) might provide a suitable framework for vaccine development.
The test vaccine consisted of 1 μg ClfA, 50 μg CpG and 1% w/v Alhydrogel an aluminium
based adjuvant, components which have been used previously [37–39]. Mice were vaccinated
on days 0, 14 and 21 before S. aureus infection on day 28, with blood drawn before and after
vaccinations (Fig 6A). The vaccine was tested for efficacy, alongside PBS control injections, in
three S. aureus infection scenarios; low dose (1x106 S. aureus), high dose (1x107 S. aureus) and
augmented low dose (1x106 S. aureus +/- M. luteus PGN), in 2 independent experiments (Figs
6 and S7). Low dose infection caused low numbers (an average of 38 CFU) of bacteria in the
liver, with more observed in the high dose infection (an average of 1.43x106 CFU), and as
expected, the augmentation groups had very high liver bacterial numbers (an average of
4.45x107 CFU) (Fig 6B). Interestingly, vaccination reduced S. aureus liver and kidney bacterial
numbers only for the augmentation groups (Figs 6B and S7A, S7B). The second independent
experiment also showed that the vaccine was only effective in reducing S. aureus pathogenesis
in the augmented scenario (S7C–S7F Fig). These data suggest that using augmentation to
examine vaccine efficacy may be a useful strategy, as it mimics natural infection.
Discussion
S. aureus is an insidious pathogen made more concerning due to the spread of antimicrobial
resistance and the lack of an available vaccine. Understanding infection dynamics provides a
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route to the identification of disease breakpoints where interventions might be most effective.
An effective vaccine should be able to prevent disease establishment, and so understanding the
status of the pathogen at this infection initiation stage is crucial. All pathogens exist within a
polymicrobial environment from which they emerge to cause disease. S. aureus lives as a
human commensal, primarily in the nares where even in this niche it forms only a small pro-
portion of the microbiome [1–3]. Thus, all S. aureus infections are initiated from an inoculum
that is mostly not the pathogen. With this backdrop, we have identified the augmentation phe-
nomenon, where human-skin commensals or derivatives enhance S. aureus pathogenesis, act-
ing at the level of initial macrophage interaction [12]. The amount of material required to
augment S. aureus infection is comparable to the number of bacteria located on human skin or
vascular catheters [40,41]. Here we find that augmentation is not specific to S. aureus as it
occurs with other opportunist pathogens. Both E. coli and E. faecalis, which survive intracellu-
larly within macrophages [42,43], benefitted from augmenting material. However, in both
cases augmentation was evidenced by reduced clearance rather than an increase in pathogen
load, suggesting the increase in pathogenesis resulting in increased bacterial burden may be
peculiar to S. aureus. We also show S. aureus disease can be augmented by a range of particu-
late materials from whole bacteria to fungal cell walls, suggesting that augmentation is not
mediated by a response to specific components. This is supported by our previous work that
demonstrated augmentation not to require any of the major host response pathways such as
NOD1 and NOD2 [12]. The hypothesis that augmentation occurs at the initiation of infection
was further supported by the requirement for co-inoculation of S. aureus and augmenting
material.
Fig 6. Vaccination reduces augmented infection. A-BMice were vaccinated subcutaneously on day 0, 14 and 21 with
vaccine (1 μg ClfA, 50 μg CpG and 1% w/v Alhydrogel, triangles) or PBS control (circles). Day 28 post-vaccination
mice were intravenously injected with low dose S. aureus (1x106 CFU) high dose S. aureus (1x107 CFU), with both low
dose S. aureus and 250 μgM. luteus PGNA diagram of experimental protocol B liver CFUs, enumerated 72 hpi (n = 10
per group, median value shown, two-tailed Mann-Whitney test), ��p<0.002.
https://doi.org/10.1371/journal.ppat.1009880.g006
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Augmentation has a profound effect on S. aureus disease, resulting in the ability to reduce
the required inoculum by 1000-fold to cause systemic disease in the murine sepsis model [12].
To determine what the molecular mechanism might be, we homed in on those events which
occur within the macrophage after phagocytosis, where ROS production is known to be
required for augmentation [12]. In vitro, augmenting material protected S. aureus from H2O2,
HOCl and peroxynitrite, suggesting that augmenting material reacts with ROS acting as a
buffer, allowing continued S. aureus survival. Augmenting material showed a variable, protec-
tive capacity against different ROS. As an example, low dose HKM. luteus (equivalent CFU
5x106) protected WT S. aureus from killing by HOCl but not the other ROS tested (Figs 3E
and S4C, S4D). Conversely, PGN (25 mg/ml) was able to protect S. aureus from H2O2, peroxy-
nitrite and HOCl (Fig 3B–3D). Use of a higher dose of HKM. luteus (equivalent CFU
1.25x108), which was comparable to the number of live cells from which the PGN was derived
gave protection to all 3 ROS demonstrating parity (Fig 3F and 3G). LiveM. luteus, at a concen-
tration of 106 CFU, was able to protect S. aureus from ROS killing by HOCl, H2O2 and peroxy-
nitrite, which is likely due in part toM. luteus ROS resistance enzymes, such as catalase. A
variety of biological entities present on augmenting material hold the potential to react with
ROS resulting in, for example, oxidation or chlorination [44,45]. Furthermore, pre-treatment
of augmenting material with ROS inhibited its protective ability, defining a finite capacity for
ROS detoxification. The in vitro data was obtained in an environment very different from that
experienced by the bacteria inside phagocytes, let alone in vivo, therefore it was important to
make analyses in these more complex milieu. There are a range of ROS, all ultimately originat-
ing from superoxide as a product of NADPH oxidase, but which are directly involved in S.
aureus killing in macrophages is unknown [26]. S. aureus katA ahpC is susceptible to H2O2 in
vitro and is attenuated in vivo. Interestingly, augmentation had a dramatic effect on S. aureus
katA ahpC pathogenesis resulting in extremely boosted virulence, to a level compatible to its
parent. This embeds the role of ROS resistance at the very earliest stages of disease in order to
pass the initial threshold of infection establishment. H2O2 is produced early during oxidative
burst [16,17,46] and may therefore constitute a key ROS in controlling S. aureus. We also
found that augmenting material protects S. aureus from HOCl and that pre-treatment of the
augmentor with this ROS abrogated its protective effect. HOCl is derived from H2O2 by MPO
within macrophages but at a proposed lower level than in neutrophils [47], leading to a higher
H2O2 concentration in macrophages [48]. Nevertheless, here we demonstrated that MPO is an
important host defence enzyme in vivo, where its loss resulted in increased bacterial load in
the liver highlighting HOCl as an important ROS in the control of infection. Lack of MPO did
not prevent augmentation, in contrast to the loss of NOX2 activity in mice which did [12]. It is
therefore likely that augmenting material acts as a sink for ROS in general thereby protecting
S. aureus and allowing it to survive this crucial phase in host innate defences.
The effect of augmenting material is to allow S. aureus to survive the ROS assault in the
macrophage. Inhibition of ROS in the absence of augmenting material did not greatly enhance
S. aureusmass formation in isolated macrophages, possibly indicating that other killing mech-
anisms, of which there are a variety [26], may compensate in vitro. When S. aureus infection is
augmented, absorption of ROS by augmenting material may prevent further maturation of the
phagosome and thus activation of downstream bactericidal mechanisms. However, the impor-
tance of host ROS in controlling S. aureus infection real-life infections is clearly demonstrated
with increased S. aureus pathogenicity in MPO (or NOX2 [12]) deficient mice, as well as the
attenuation of S. aureus katA ahpC infection in vivo. A model for the molecular mechanism of
augmentation is shown in S8 Fig, where phagocytosis of a threshold number of S. aureus leads
to activation of ROS production and bacterial killing. Augmentation results in a bolus of
phagocytosed material in addition to the S. aureus that acts to detoxify ROS and so increase
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the chance of bacterial survival, subsequent proliferation and lysis of the phagocyte, releasing a
cluster of bacteria able to further multiply to form a microabscess. It is these microabscesses
that can then go onto seed other sites in the host leading to a systemic and potentially fatal
infection. Augmentation may act, therefore, to increase chances of infection spread by expand-
ing the number of macrophages that are ineffective at controlling the initial infective dose. As
the initiation of human infection will come from a polymicrobial environment, augmentation
provides a framework to test prophylactic regimen. Indeed, under an augmentation scenario,
an experimental S. aureus vaccine reduced bacterial burden. Understanding infection dynam-
ics and the interplay between pathogen, host and other organisms is beginning to give insight
into disease progression, and how novel interventions to sway the outcome in the favour for
the host may be derived.
Materials andmethods
Ethics statement
Animal work in the UK was performed in accordance with the Animal (Scientific Procedures)
Act 1986. At the University of Sheffield, work was completed under project licences
P3BFD6DB9 and PPL 40/3699 for murine work, or P1A4A7A5E for zebrafish work, with ethi-
cal approval from the University of Sheffield Local Ethical Review Panel. At Imperial College
London, work was conducted under licence P4C824899 with approval from the Imperial ethi-
cal review board. At INRAE, animal work was approved by the local ethics committee
(COMETHEA or “Comité d’Ethique en Expérimentation Animale”, Centre de Recherche Ile
de France—Jouy en Josas–Antony) under the registration numbers 15_08, and by the French
Ministry of Higher Education and Research APAFIS #480-2015041518048149v1, where all
animal experiments were performed in accordance with European directive 2010/63/EU. Ani-
mal experiments in Calgary were approved by the University of Calgary Animal Care Commit-
tee and were in compliance with the Canadian Council for Animal Care Guidelines (protocol
nr. AC16-0148). MDMs were derived, with informed consent, from the blood of healthy vol-
unteers, in accordance with guidelines from the South Sheffield Research Ethics Committee
(07/Q2305/7).
Animal husbandry
Mice were housed in designated animal facilities in standard husbandry conditions. BALB/c
female mice aged 6–9 weeks (Charles River Laboratories) for all animal work completed at the
University of Sheffield. At the University of Calgary female and male MPO-/- Mice and C57
wild-type controls aged 8–11 weeks (Jackson Laboratory) were used. Adult zebrafish were
maintained according to standard protocols in UK home office approved facilities, at the Bate-
son centre Aquaria at the University of Sheffield. Embryos less than 5.2 days post-fertilisation
(dpf) of Tg(mpeg1:mCherryCAAX)sh378 [35] were used.
Murine models
The mouse sepsis model was completed by injecting BALB/c mice with a pathogen (S. aureus,
E. faecalis, S. pneumoniae or P. aeruginosa), augmenting material (M. luteus, PGN, HKM.
luteus, HK C. neoformans, E. coli, R.mucosa or S. cerevisiae), or mixture of a pathogen and an
augmentor. These were injected into the tail vein in a volume of 100 μl. Individual experimen-
tal figure legends show the CFU and/or amount of augmenting material used. Bacteria were
prepared for injection as previously established [49], and serial dilutions of the inoculum were
plated to confirm CFUs injected into mice. Mice were monitored daily for health and weight,
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and were euthanised at the experimental end point of 48 or usually 72 hours post-infection
(hpi). Liver and kidney CFU were calculated as previously established [12].
For murine intramuscular injections, mice were challenged intramuscularly with S. pyo-
genes, with or without 500 μgM. luteus PGN in 50 μl PBS and quantitative endpoints com-
pared at 24 hpi. Mice were euthanised and thigh muscle dissected and then homogenised.
Bacterial CFU counts were determined by plating of homogenised tissue and blood samples
onto the specified agar, with or without dilution in PBS, as appropriate.
In the subcutaneous mouse injections used in the vaccine experiments, mice were scruffed
and injected subcutaneously into the scruff with 100 μl of vaccine or PBS control.
For murine blood sampling, mice were warmed to 37 oC to promote tail vein dilation, a
small cut was made into the tail vein allowing a small volume of blood to be collected.
Zebrafish infection model
For zebrafish infection and imaging, the established zebrafish infection model was followed
[50]. Immediately prior to injection, PGN was stained with Alexa Fluo 405 NHS Ester (Fisher)
following established protocols [51]. 2 dpf larvae were anesthetized with tricaine and injected
with 1 nl containing 400 CFU of GFP-S. aureus, 5 ng of stained PGN, or both, into the yolk sac
circulation valley. Larvae were then recovered, before being mounted in 0.8% low melt agarose
(Affymetrix, 32830) in glass-bottom microwell dishes (MatTek, P35 G-1.5–14 C). An Ultra-
VIEW VoX spinning disk confocal microscope (Perkin Elmer, Cambridge, UK) was used for
imaging larvae at 2 hpi, where 405 nm, 445 nm, 488 nm, 514 nm, 561 nm and 640 nm lasers
were available for excitation and a 40x oil objective (UplanSApo 40x oil [NA 1.3] was used.
Imaging of macrophages were obtained in the caudal hematopoietic tissue (CHT). Analysis was
carried out using Fiji (ImageJ) to measure the area of macrophages, and S. aureus and PGN
within macrophages. 47 macrophages from 21 zebrafish larvae which had been co-injected with
S. aureus and PGN were assessed for the presence of phagocytosed S. aureus, PGN or both.
Bacterial strains and culture
Microbial strains used in this study are listed in Table 1.
Transductions
S. aureusNewHG katA, ahpC and katA ahpC strains were created using established transduc-
tion protocols [21] using ϕ11, from existing S. aureus SH1000 katA (KS100) [21] or ahpC
(KC041) [21] strains. Presence of mutations in the newly generated NewHG strains were con-
firmed with PCR. The NewHG-mCherry (SJF4439) was created following the same transduc-
tion protocols [21] using an existing SH1000-mCherry strain [13].
Peptidoglycan and capsule preparation
M. luteus or S. aureus PGN used throughout this study was prepared and purified using estab-
lished protocols [55]. C. neoformans capsule was isolated after growing cultures for 7 days at
28˚C at 180 rpm. The culture was autoclaved, cells harvested at 6000 g, and supernatant col-
lected. Ice-cold ethanol was added to precipitate the cryptococcal capsule, which was collected
after centrifugation again at 6000 g.
Vaccine preparation
Vaccine formulations were made in 1x endotoxin free PBS. Vaccines were used at a final con-
centration of 1 μg/dose Clumping factor A (ClfA, recombinant, endotoxin purified, mass-
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spectrometry confirmed), 50 μg/dose CpG-B DNA (Hycult Biotech), 1% (w/v) Alhydrogel an
aluminium based adjuvant (Invivogen). Vaccines were always administered subcutaneously,
as above.
For the production of ClfA, XL1 blue E. coli were used to produce recombinant 6xHis
tagged ClfA (residues 40–559). ClfA was purified from cell lysates via nickel affinity chroma-
tography, size exclusion chromatography and confirmed as endotoxin-free. Finally, mass spec-
trometry was used to verify ClfA (residues 40–559) identity.
In vitro ROS challenge assays
To generate ROS-killedM. luteus, bacteria were treated with ROS (sodium hypochlorite, H2O2
or peroxynitrite) until colonies would no longer form on agar. An aliquot of ROS-killed sus-
pension was then dried and weighed to determine concentration, before freezing to -20˚C in
PBS.
S. aureus andM. luteus from overnight broth cultures were adjusted to an optical density at
600 nm (OD600) of 0.05 and 0.1, respectively, in 50 mL TSB. Bacteria were grown at 37˚C (S.
aureus) or 30˚C (M. luteus) for 2 h, shaking. Bacteria were harvested and resuspended in PBS
to OD600 1.0 for S. aureus, or 11.3 forM. luteus. S. aureus andM. luteus were diluted to 2x10
5
CFU/mL and 2x107 CFU/mL, respectively, in PBS. HK and ROS-killedM. luteus were diluted
to equivalent concentrations to liveM. luteus, as determined by dry weight (approximately 3.2
Table 1. Bacterial and fungal strains used.
Species Strain Description Culture conditions Reference or source
Staphylococcus
aureus












pMV158-mCherry lysA::kan lysA+ TSB (Kanamycin 50 μg/mL and


















ahpC::tet TSB (Tetracycline 5 μg/mL), 37˚C This study
Micrococcus luteus SJF4393 ATCC 4698 (RifR) TSB (Rifampicin 0.1 μg/mL), 30˚C [12]





H584 M1T1 invasive puerperal sepsis blood
isolate
Columbia horse blood agar, 37˚C [53]
Streptococcus
pneumoniae





PA01 Wild-type Luria-Bertani (LB), 37˚C Lab stock
Cryptococcus
neoformans
H99 Lab reference strain derived from
Heitman lab, H99 #1
Grown in YPD, 28˚C, then heat-killed. [54]
Escherichia coli W3110
(SJF4060)
Wild-type LB Lab stock




842 (SJF 66) Wild-type Grown in YPD at 30˚C Lab stock
https://doi.org/10.1371/journal.ppat.1009880.t001
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mg/mL). 50 μL S. aureus was incubated in the presence of 50 μL live, HK or ROS-killedM.
luteus, orM. luteus PGN (25 mg/ml), with ROS and PBS to a total volume of 200 μL. S. aureus
was incubated alone, with or without ROS for positive and negative controls. An aliquot of live
bacteria present in individual tubes was taken prior to addition of ROS to determine CFU/mL
at the start of the assay. H2O2 (VWR) was used at a final concentration of 0.0077% v/v, peroxy-
nitrite (Sigma-Aldrich) at a final concentration of 2.25 mM, methyl viologen (Sigma-Aldrich)
at a final concentration of 1.8 M, and sodium hypochlorite (Fisher) at a final concentration of
0.00005% v/v. Tubes were incubated at 37˚C, shaking, for 1 h before determination of CFU/
mL by serial dilutions. Experimental data was combined from 3 replicates carried out on sepa-
rate days.
Cell culture
Experiments were conducted with RAW264.7 cells (ATCC TIB-71), a leukemic murine mac-
rophage cell line, or primary MDMs derived from human blood. RAW264.7 cells were culti-
vated in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 2 mM
L-Glutamine, 100 Units/mL streptomycin, 0.1 mg/mL penicillin, and 10% v/v Foetal bovine
serum (FBS) (all media components sourced from Sigma-Aldrich). RAW264.7 cells were pas-
saged into fresh media upon reaching 70–80% confluence. All experiments carried out
between passages 5 and 20.
MDMs were isolated as described previously [56]. Briefly, peripheral blood mononuclear
cells were isolated by Ficoll Plaque (GE Healthcare) density centrifugation, seeded in 24 well
plates at 2x106 cells/well in RPMI-1640 media (Lonza) supplemented with 2 mM L-Glutamine,
10% v/v newborn calf serum (Gibco) and incubated at 37˚C, 5% CO2. Non-adherent cells were
removed after 24 h, and adherent cells were fed with fresh RPMI-1640 supplemented with 2
mM L-Glutamine and 10% v/v low endotoxin heat-inactivated foetal bovine serum (Biosera).
MDMs were used for experiments at 14 days post-isolation. Media was replaced every 2–3
days for all cells used.
Cell infection
Cell infection assays were carried out as similar to those described previously [12], with modi-
fication. RAW264.7 or MDM cells were seeded into 24 well plates (Corning) or white 96 well
micro-clear plates (Greiner) and grown to 80% confluence. DMEM supplemented with 2 mM
L-glutamine was used in experimental assays for RAW264.7 cells. Cell monolayers were
washed with tissue culture PBS (Fisher) three times before infection to remove residual
antibiotic.
S. aureus was thawed from a frozen aliquot, as for mouse experiments. Unless otherwise
stated, S. aureus was added to cells at a multiplicity of infection (MOI) 5, and HKM. luteus at
MOI 50.
S. aureusmacrophage survival and mass formation assay
For experiments concerning S. aureusmass formation, GFP expressing S. aureus was added to
cells with or without HKM. luteus in 96 well plates and incubated at 37˚C, 5% CO2 for 2.5 h.
Media was removed and fresh infection media supplemented with 20 μg/mL lysostaphin (Bio-
synexus), alongside 100 μg/ml gentamycin (Fisher) for MDMs, was added and incubated for
0.5–1 h at 37˚C, 5% CO2 to kill extracellular bacteria. Monolayers were washed with PBS three
times, fresh media was added and incubated overnight at 37˚C, 5% CO2. Wells were imaged at
24 h post-infection using ImageXpress Micro (Molecular Devices), using a 2x objective lens
and FITC filter. Masses were analysed using MetaXpress high-content image acquisition and
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analysis software (Molecular Devices) for average number of masses larger than 20–40 μm per
well. Experiments into the effects of chemicals on S. aureusmass formation were carried in the
presence of 2 μM diphenyleneiodonium chloride (DPI), 500 μM apocynin or 1 μMMito-
TEMPO, all sourced from Sigma-Aldrich, with media supplemented with solvent used for
controls.
In a modification of this experiment, the ratio of S. aureus to HKM. luteus was altered.
RAW264.7 cells were infected with GFP S. aureus (MOI 5) in the presence or absence of HK
M. luteus at a ratio to S. aureus of 10 (MOI 50), 5 (MOI 25), 2.5 (MOI 12.5), 0.5 (MOI 2.5), or
0.05 (MOI 0.25). Alternatively, RAW264.7 cells were infected with GFP S. aureus at MOI 5,
2.5, 1.25, 0.25, 0.025 in the presence or absence of HKM. luteus (MOI 50).
Hydrop dye
For experiments using Hydrop fluorescent dye (Goryo chemical), mCherry S. aureus was
stained with Alexa Fluor 555 NHS Ester (Fisher) [51] S. aureus were stored on ice until addi-
tion to RAW264.7 cells in a 24 well plate. S. aureus (MOI 5) and/or HKM. luteus (MOI 50)
were added to cells in the presence of 1 μMHydrop dye. 200 nM PMA with Hydrop dye was
added to cells for positive control. Wells were imaged at 30 min post-infection on a Nikon
Eclipse Ti microscope was used to image cells in a climate controlled set-up (37˚C, Atmo-
sphere: 5% CO2 / 95% air) with a x20 Lambda Apo NA 0.75 phase contrast objective for bright-
field or with GFP or mCherry filters, images were captured with a Andor Neo-5.5-CL3
camera. Analysis was carried out using NIS elements (Nikon) and Fiji (ImageJ). The threshold
for GFP images was adjusted within Fiji to exclude background fluorescence. The same thresh-
old was set for all images from an experiment, and this was used to measure the fluorescence
levels.
CellROX
For experiments using CellROX deep red reagent (Fisher), S. aureus SJF4620 was first stained
with 20 μMCellROX and incubated at 37˚C for 30 min, shaking. Labelled S. aureus (MOI 50)
were added to RAW264.7 cells in the presence or absence of HKM. luteus, with unlabelled
GFP S. aureus or blank media used for controls. Cells were incubated at 37˚C, 5% CO2 for 30
min before fixation with 2% w/v paraformaldehyde (Sigma) for 1 h. Following fixation, sam-
ples were washed thoroughly with PBS and stained with 300 nM DAPI (Fisher) before further
PBS washes. Samples were imaged on ImageXpress Micro (Molecular Devices) using a 20x
objective lens, DAPI, FITC and Cy5 filters. Images were analysed using MetaXpress high-con-
tent image acquisition and analysis software. A custommodule editor was used to identify bac-
teria in the GFP and Cy5 filters and count the frequency of signal overlap (referred to as
‘oxidised objects’).
S. aureus infection of macrophages timelapse
For timelapse experiments, GFP S. aureus in the presence or absence of HKM. luteus was
added to RAW264.7 or MDM cells in a 24 well plate, and incubated on ice for 60 min, then at
37˚C, 5% CO2 for 90 min. Antibiotic-containing media was then added to cells: 20 μg/mL
lysostaphin for RAW264.7 cells, 20 μg/mL lysostaphin and 100 μg/mL gentamycin for MDMs.
This was incubated at 37˚C, 5% CO2 for 30 min. Wells were washed with PBS three times and
replaced with fresh media. MDMs were imaged every 10 min for 18 h, while RAW264.7 cells
were imaged every 20 min for 18 h. Imaging was carried out on a Nikon Eclipse Ti microscope
was used to image cells in a climate-controlled set-up (37˚C, Atmosphere: 5% CO2 / 95% air)
with a x20 Lambda Apo NA 0.75 phase contrast objective for brightfield or with a GFP filter,
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images were captured with a Andor Neo-5.5-CL3 camera. Analysis was carried out using NIS
elements (Nikon) and Fiji (ImageJ).
Statistical analysis
Statistical analysis was carried out in Prism 8.4.3 (GraphPad), with P<0.05 considered signifi-
cant. Mouse experiments were analysed using two-tailed Mann-Whitney U tests or Kruskal-
Wallis one-way analysis of variance (ANOVA) tests with Dunn’s post-test, depending on the
number of groups compared. Zebrafish experiments were analysed using unpaired t-tests. In
vitro ROS challenge assays were analysed using one-way ANOVAs with Tukey post-test. Cell
infection assays were analysed by Mann-Whitney U tests or Kruskal-Wallis ANOVA tests with
Dunn’s post-test. All measurements were taken from distinct samples.
Supporting information
S1 Fig. Breadth of the augmentation phenomenon. A Co-injection of low dose S. aureus (SA
1x106 CFU) with heat-killedM. luteus (HKML equivalent of 1x108 CFU) into mice: weight
loss (n = 5 per group), �p<0.05 B Co-injection of low dose S. aureus (SA 1x106 CFU) with E.
coli (EC 5x106 CFU) into mice: weight loss (n = 8–10 per group, S. aureus, circles; E. coli trian-
gles), ��p<0.003; ���p<0.0005 C Co-injection of low dose S. aureus (SA 1x106 CFU) with R.
mucosa (RM 2x108 CFU) into mice: weight loss (n = 5 per group)D Co-injection of low dose
S. aureus (SA 1x106 CFU) with heat-killed C. neoformans (CN 750 μg) into mice: weight loss
(n = 9–10 per group) E-G Co-injection of low dose S. aureus (SA 1x106 CFU) with S. cerevisiae
(SC 1x108 CFU) into mice, (n = 10 per group, S. aureus, circles; S. cerevisiae triangles): E
weight loss, �p<0.05; ����p<0.0001, F liver CFU, ����p<0.0001, G kidney CFU, ���p<0.0005
H-L Co-injection of low dose E. faecalis (EF 5x107 CFU) withM. luteus (ML 2x108 CFU) into
mice:H weight loss (n = 10 per group), I kidney CFU, J lung CFU, �p�0.05, K heart CFU, L
spleenM-N Co-injection of low dose E. faecalis (EF 5x107 CFU) withM. luteus PGN (ML
PGN 500 μg) into mice (n = 10 per group):M weight loss, �p<0.05,N liver CFU,O-R Co-
injection of high dose E. faecalis (EF 1x108 CFU) withM. luteus PGN (ML PGN 500 μg) into
mice, CFUs taken at 48 hpi (n = 8–9 per group):O liver CFU, ����p<0.0001, P kidney CFU,
��p<0.0.003,Q spleen CFU, ���p<0.0.0005, R heart CFU, �p<0.05. Colours used indicate the
level of significance as indicated in Fig 1E. For all panels, the median value is shown. For panels
B and E, a Kruskal-Wallis test with Dunn’s post-test was used, for all remaining panels a two-
tailed Mann-Whitney test was used. CFUs were enumerated at 3 days post-infection, unless
otherwise stated.
(TIF)
S2 Fig. Lack of augmentation of alternative bacterial pathogens. A-C Co-injection of low
dose S. pneumoniae (SPN 1x106 CFU) withM. luteus PGN (ML PGN 500 μg) into mice
(n = 10 per group), CFUs enumerated at 3 days post-infection: A weight loss, �p<0.05, B liver
CFU, C kidney CFU, ��p<0.003D-F Co-injection of low dose P. aeruginosa (PA 1x105 CFU)
withM. luteus PGN (ML PGN 500 μg) into mice (n = 10 per group), CFUs enumerated at 3
days post-infection:D weight loss, E liver CFU, F kidney CFUG-H Intramuscular co-injection
of S. pyogenes (SPY 1x108 CFU) withM. luteus PGN (ML PGN 500 μg) into mice (n = 8 per
group): G leg hindlimb CFU at 24 hpi,H weight loss at 24 hpi. Colours used indicate the level
of significance as indicated in Fig 1E. For all panels, a two-tailed Mann-Whitney test was used
and the median value is shown.
(TIF)
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S3 Fig. Augmenting material must be present at the same time and location as S. aureus to
enhance infection. A-BMice were intravenously injected with 500 μgM. luteus PGN 24
hours, 6 hours or 1 hour before infection with 1x106 S. aureus, at the same time as S. aureus, or
with S. aureus alone (n = 7 per group, median value shown, Kruskal-Wallis tests with Dunn’s
post-test) A weight loss B kidney CFU C-DMice were intravenously injected with 500 μgM.
luteus PGN 48 hours, 24 hours or 6 hours after infection with 1x106 S. aureus, at the same time
as S. aureus, or with S. aureus alone (n = 5 per group, median value shown, Kruskal-Wallis
tests with Dunn’s post-test) C weight loss, �p<0.05; ��p<0.008D kidney CFU E quantitation
of zebrafish macrophages from Fig 2I, showing the percentage containing S. aureus only
(green), PGN only (blue) or S. aureus co-localising with PGN (yellow) (n = 47 macrophages
from 21 larvae).
(TIF)
S4 Fig. Augmenting material protects S. aureus from ROS in vitro. A Following methyl vio-
logen exposure, percentage survival of S. aureus alone (5x104 CFU/mL), or withM. luteus
PGN (1.25 mg) (n = 3, error bars show mean +/- SD, one-way ANOVA test with Tukey’s post
hoc test), �p<0.05; ��p<0.01 B-D Following ROS exposure, percentage survival of S. aureus
alone (5x104 CFU/mL), or with liveM. luteus (5x106 CFU/mL), heat-killedM. luteus (equiva-
lent of 5x106 CFU/mL) or ROS killedM. luteus (equivalent of 5x106 CFU/mL), (n = 3, error
bars show mean +/- SD, one-way ANOVA tests with Tukey’s post hoc test) Bmethyl viologen,
����p<0.0001 C hydrogen peroxide, ��p<0.007D peroxynitrite, ��p<0.003; ����p<0.0001 E
Following sodium hypochlorite exposure, percentage survival of S. aureus alone (5x104 CFU/
mL), or with liveM. luteus (5x106 CFU/mL), (n = 3, error bars show mean +/- SD, one-way
ANOVA test with Tukey’s post hoc test), �p<0.05.
(TIF)
S5 Fig. ROS susceptible S. aureus survives ROS exposure due to protection by augmenting
material. A-B Following hydrogen peroxide exposure, percentage survival of ROS susceptible
S. aureusmutants alone (5x104 CFU/mL), or with liveM. luteus (5x106 CFU/mL), heat-killed
M. luteus (equivalent of 5x106 CFU/mL) or H2O2 killedM. luteus (equivalent of 5x10
6 CFU/
mL), (n = 3, error bars show mean +/- SD, one-way ANOVA tests with Tukey’s post hoc test):
A katA, �p<0.05 B ahpC, �p<0.05; ���p<0.0007 C Following sodium hypochlorite exposure,
percentage survival of S. aureus katA ahpC alone (5x104 CFU/mL), or with liveM. luteus
(5x106 CFU/mL), heat-killedM. luteus (equivalent of 5x106 CFU/mL) or ROS killedM. luteus
(equivalent of 5x106 CFU/mL), (n = 3, error bars show mean +/- SD, one-way ANOVA test
with Tukey’s post hoc test), ����p<0.0001D-F Injection of high dose (1x107) of S. aureus con-
trol, katA, katA ahpC into mice (n = 10 per group, median value shown, Kruskal-Wallis tests
with Dunn’s post-test):D weight loss, ��p<0.009; ���p<0.0003 E liver CFU, �p<0.05 F kidney
CFUs, �p<0.05; ��p<0.01G-I Injection of high dose (1x107) of S. aureus control and ahpC
into mice (n = 10 per group, median value shown, two-tailed Mann-Whitney tests): G weight
loss, �p<0.05H liver CFU, ���p<0.0002 I kidney CFU J-K Co-injection of low dose (1x106
CFU) S. aureus katA ahpC with heat-killedM. luteus (equivalent of 1x108 CFU) into mice:
liver CFU (n = 5 per group, median value shown, two-tailed Mann-Whitney tests): J weight
loss K kidney CFU L Co-injection of low dose S. aureus (SA 2x105 CFU) withM. luteus PGN
(ML PGN 500 μg) into wild-type (WT) control mice or MPO-/-mice: weight loss (n = 9 per
group, median value shown, individual two-tailed Mann-Whitney tests), �p<0.05; ��p<0.004.
(TIF)
S6 Fig. Augmenting material protects S. aureus from ROS in murine and human macro-
phages. A Representative images of human MDMs infected with GFP S. aureus (MOI 5) in the
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presence or absence of heat-killedM. luteus (MOI 50), showing number of GFP S. aureusmas-
ses observed (n = 3, individual images show a single field of view, 4 per well), scale 100 μm B S.
aureus-GFP growth curve in the presence of 0, 2, 5 or 10 μMDPI C S. aureus-GFP growth
curve in the presence of 500 μM apocynin or solvent controlD Representative images of
RAW264.7 cells in the presence of Hydrop (1 μM) (green) incubated alone (media), treated
with PMA (200 nM), or infected with S. aureus (MOI 5), heat-killedM. luteus (MOI 50), or
both S. aureus and heat-killedM. luteus, scale 20 μm E Representative images of RAW264.7
cells incubated alone (media), infected with S. aureus (MOI 50), CellROX-stained S. aureus
(MOI 50) or CellROX-stained S. aureus (MOI 50) and heat-killedM. luteus (MOI 50).
RAW264.7 nuclei were stained with DAPI (blue), S. aureus was labelled by GFP expression
(green) and, upon oxidation, by CellROX (red). Arrows indicate co-localisation of GFP S.
aureus with CellROX signal, implying oxidation of bacteria, scale 50 μm.White box indicates
area of increased magnification, scale 10 μm.
(TIF)
S7 Fig. Vaccination reduces augmented infection. A-BMice were vaccinated subcutaneously
on day 0, 14 and 21 with vaccine (1 μg ClfA, 50 μg CpG and 1% w/v Alhydrogel, triangles) or
PBS control (circles). Day 28 post-vaccination mice were intravenously injected with low dose
S. aureus (1x106 CFU), high dose S. aureus (1x107 CFU), or both low dose S. aureus and 250 μg
M. luteus PGN (n = 10 per group, median value shown, two-tailed Mann-Whitney tests) A
weight loss, �p<0.05 B kidney CFU, �p<0.05 C-FMice were vaccinated subcutaneously on
day 0, 14 and 21 with vaccine (1 μg ClfA, 50 μg CpG and 1% w/v Alhydrogel, triangles) or PBS
control (circles). Day 28 post-vaccination mice were intravenously injected with high dose S.
aureus (5x106 CFU), or low dose S. aureus (5x105 CFU) and 250 μgM. luteus PGN (n = 10 per
group, median value shown, two-tailed Mann-Whitney tests) C diagram of experimental pro-
tocolD liver CFU, ����p<0.0001 E weight loss, �p<0.05; ��p<0.006 F kidney CFU.
(TIF)
S8 Fig. Diagram of augmentation phenomenon mechanism. Diagram highlighting how aug-
menting material protects S. aureus from ROS in the phagosome of macrophages. The left-
hand side demonstrates non-augmented S. aureus infection, resulting in ROS mediated bacte-
rial killing. The right-hand side shows an augmented S. aureus infection, highlighting how the
presence of augmenting material in the same phagosome as S. aureus results in reduced S.
aureus killing due to inactivating ROS produced in the phagosome. Survival S. aureus is then
able to proliferate and escape the macrophage.
(TIF)
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baud, Matthew K. Siggins, Eric J. G. Pollitt, Simon A. Johnston.
Methodology: Josie F. Gibson, Grace R. Pidwill, Oliver T. Carnell, Bas G. J. Surewaard, Daria
Shamarina, Joshua A. F. Sutton, Charlotte Jeffery, Aurélie Derré-Bobillot, Cristel Archam-
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